Table 1 Characteristics of the participants at baseline and 1st post-trial visit
Characteristics | Baseline | P | 1st post-trial visit | P | ||
|---|---|---|---|---|---|---|
Fenofibrate (n = 484) | Placebo (n = 456) | Fenofibrate (n = 395) | Placebo (n = 370) | |||
Age | 61.4 ± 6.2 | 62.2 ± 6.7 | 0.04 | 67.2 ± 6.3 | 67.6 ± 6.6 | 0.32 |
Sex | 0.96 | 0.59 | ||||
Male | 388 (80.2%) | 364 (79.8%) | 319 (80.8%) | 292 (78.9%) | ||
Female | 96 (19.8%) | 92 (20.2%) | 76 (19.2%) | 78 (21.1%) | ||
Years of diabetes | 9.2 ± 6.6 | 9. 6 ± 6.6 | 0.37 | 14.6 ± 6.5 | 15.2 ± 6.6 | 0.22 |
Ethnicity | 0.17 | 0.51 | ||||
White | 365 (75.4%) | 362 (79.4%) | 305 (77.2%) | 294 (79.5%) | ||
Non-White | 119 (24.6%) | 94 (20.6%) | 90 (22. 8%) | 76 (20.5%) | ||
CVD history | 0.93 | 0.98 | ||||
Yes | 195 (40.3%) | 186 (40.8%) | 153 (38.7%) | 142 (38.4%) | ||
No | 289 (59.7%) | 270 (59.2%) | 242 (61.3%) | 228 (61.6%) | ||
BG trial assignment | 0.36 | 0.36 | ||||
Intensive group | 251 (51.8%) | 222 (48.7%) | 203 (51.4%) | 177 (47.8%) | ||
Standard group | 233 (48.2%) | 234 (51.3%) | 192 (48.6%) | 193 (52.2%) | ||
HbA1c (%) | 8.4 ± 1.1 | 8.4 ± 1.0 | 0.94 | 7.9 ± 1.9 | 7.6 ± 1.3 | 0.07 |
SBP (mm Hg) | 134.1 ± 17.6 | 133.9 ± 18.6 | 0.87 | 131.0 ± 17.1 | 131.8 ± 17.3 | 0.66 |
CHOL (mg/dl) | 187.0 ± 38.5 | 189.0 ± 42.1 | 0.45 | 154.6 ± 42.5 | 152.8 ± 32.8 | 0.64 |
TG (mg/dl) | 327.2 ± 125.3 | 325.0 ± 154.2 | 0.81 | 216.6 ± 124.1 | 222.7 ± 115.2 | 0.61 |
VLDL-C (mg/dl) | 61.2 ± 18.6 | 61.2 ± 25.4 | 0.97 | 41.4 ± 20.8 | 42.63 ± 20.1 | 0.55 |
LDL-C (mg/dl) | 96.3 ± 32.0 | 98.4 ± 32.9 | 0.34 | 79.2 ± 32.7 | 76.6 ± 26.1 | 0.38 |
HDL-C (mg/dl) | 29.5 ± 3.8 | 29.5 ± 3.7 | 0.76 | 33.9 ± 7.3 | 33.6 ± 7.2 | 0.60 |